Tim MBA - HLS Therapeutics Chief Officer
| HLTRF Stock | USD 2.60 0.17 7.00% |
Insider
Tim MBA is Chief Officer of HLS Therapeutics
| Age | 51 |
| Phone | 647 495 9000 |
| Web | https://www.hlstherapeutics.com |
HLS Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0276) % which means that it has lost $0.0276 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1442) %, meaning that it generated substantial loss on money invested by shareholders. HLS Therapeutics' management efficiency ratios could be used to measure how well HLS Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniela Marino | Knight Therapeutics | N/A | |
| Julia Bouvet | Cannara Biotech | N/A | |
| David Young | Centr Brands Corp | 42 | |
| Arthur Danner | Centr Brands Corp | N/A | |
| Francois Lafortune | Crescita Therapeutics | N/A | |
| Patricia Colvin | Bionoid Pharma | N/A | |
| Brian Sherman | Cannara Biotech | N/A | |
| Leopoldo Bosano | Knight Therapeutics | N/A | |
| David Abitbol | Cannara Biotech | N/A | |
| Arjan Chima | Centr Brands Corp | 40 | |
| Anthony Manouk | Cannara Biotech | N/A | |
| Zohar Krivorot | Cannara Biotech | 46 | |
| Alexander Wolfe | Cannara Biotech | N/A | |
| Arvind Utchanah | Knight Therapeutics | N/A | |
| Etienne Ledoux | Cannara Biotech | N/A | |
| Avi Krivorot | Cannara Biotech | N/A | |
| Susan Emblem | Knight Therapeutics | N/A | |
| BA BA | Knight Therapeutics | 53 | |
| Jody Engel | Knight Therapeutics | N/A | |
| Dominic KingSmith | Crescita Therapeutics | N/A | |
| France Landry | Cannara Biotech | N/A | |
Management Performance
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0276 |
HLS Therapeutics Leadership Team
Elected by the shareholders, the HLS Therapeutics' board of directors comprises two types of representatives: HLS Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HLS. The board's role is to monitor HLS Therapeutics' management team and ensure that shareholders' interests are well served. HLS Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HLS Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA LLB, CoFounder Chairman | ||
| Sanjiv Sharma, Chief Officer | ||
| JD BA, HR Legal | ||
| David Spence, Co Controller | ||
| Gilbert Godin, CEO CoFounder | ||
| Tim MBA, Chief Officer |
HLS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is HLS Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0276 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 344.73 M | |||
| Shares Outstanding | 32.38 M | |||
| Shares Owned By Insiders | 6.15 % | |||
| Shares Owned By Institutions | 64.28 % | |||
| Price To Book | 1.86 X | |||
| Price To Sales | 4.41 X |
Currently Active Assets on Macroaxis
Other Information on Investing in HLS Pink Sheet
HLS Therapeutics financial ratios help investors to determine whether HLS Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.